Medical Condition

recurrent malignant solid neoplasm

Total Trials

7

Recruiting Now

7

Trial Phases

Phase 1, Phase 1, Phase 2, Phase 2

ClinicalMetric tracks all active clinical trials for recurrent malignant solid neoplasm sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — recurrent malignant solid neoplasm Clinical Trials

How many clinical trials are currently recruiting for recurrent malignant solid neoplasm?

ClinicalMetric currently tracks 7 actively recruiting clinical trials for recurrent malignant solid neoplasm, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for recurrent malignant solid neoplasm?

recurrent malignant solid neoplasm research spans Phase 1 (5 trials), Phase 2 (4 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a recurrent malignant solid neoplasm clinical trial?

Eligibility criteria for recurrent malignant solid neoplasm trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Top Sponsors

Children's Oncology Group 3 trials

University of Washington 1 trial

Anusha Kalbasi 1 trial

M.D. Anderson Cancer Center 1 trial

National Cancer Institute (NCI) 1 trial

Recruiting Clinical Trials

NCT06295965

Recruiting

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

University of Washington

View Trial →

NCT04119024 Phase 1

Recruiting

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

NCT04870944 Phase 1, Phase 2

Recruiting

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Enrollment

63 pts

Location

United States, Austr...

Sponsor

Children's Oncology Group

View Trial →

NCT06620302 Phase 1, Phase 2

Recruiting

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

Children's Oncology Group

View Trial →

NCT04851119 Phase 1, Phase 2

Recruiting

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

View Trial →

NCT04693468 Phase 1

Recruiting

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

M.D. Anderson Cancer Center

View Trial →

NCT05564377 Phase 2

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Enrollment

2,900 pts

Location

United States, Puert...

Sponsor

National Cancer Institute (NCI...

View Trial →

Related Conditions

refractory malignant solid neoplasm (4) metastatic malignant solid neoplasm (3) recurrent fallopian tube carcinoma (2) recurrent ovarian carcinoma (2) recurrent primary peritoneal carcinoma (2) ovarian carcinoma (2) advanced malignant solid neoplasm (2) clonal cytopenia of undetermined significance (1) clonal hematopoiesis (1) idiopathic cytopenia of undetermined significance (1) non neoplastic hematopoietic and lymphoid cell disorder (1) myeloid neoplasm post cytotoxic therapy (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology